<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04650698</url>
  </required_header>
  <id_info>
    <org_study_id>20-01617</org_study_id>
    <nct_id>NCT04650698</nct_id>
  </id_info>
  <brief_title>TXA in Revision Total Shoulder Arthroplasty</brief_title>
  <official_title>The Effect of Tranexamic Acid on Calculated Total Blood Loss in Patients Undergoing Revision Shoulder Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IV, randomized, single-blind, single-center study comparing calculated total&#xD;
      blood loss, surgical drain output and hematoma formation in patients who receive 2 doses of&#xD;
      Tranexamic Acid (TXA) versus control group undergoing revision total shoulder arthroplasty.&#xD;
      Patients will be randomized to either receive 2 doses of IV TXA, first dose prior to surgical&#xD;
      incision and second dose given 3 hours later or to the control group, where no TXA will be&#xD;
      administered.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of the study are to compare the effectiveness of IV TXA on reducing calculated&#xD;
      total blood loss, surgical drain output and hematoma formation in patients undergoing&#xD;
      revision total shoulder arthroplasty.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2020</start_date>
  <completion_date type="Anticipated">November 24, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Neither the anesthesiologist or surgeon will be blinded to the patient's group assignment, as they will be the one performing the treatment. All other stakeholders (patient, other caregivers, and research staff collecting the data) will be blinded to the patient's group assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total calculated total blood loss</measure>
    <time_frame>up to 24 hours post-op</time_frame>
    <description>The volume of perioperative blood loss will be determined on the basis of the blood volume and change in hemoglobin from preoperatively to 1 day postoperatively. The volume of total perioperative blood loss will be determined according to the following formula:&#xD;
Total blood loss (ml) = 1000 x 〖Hb〗_loss/〖Hb〗_i</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total surgical drain output</measure>
    <time_frame>up to 24 hours post-op</time_frame>
    <description>The floor nurse will also document the amount of blood in the indwelling hemovac surgical drain placed in the operative shoulder joint. The drain output will be documented every 8 hours. We will record the drain output for the first 16 hours after surgery - essentially 2 output shifts. If patients are in the hospital longer, we will record the third 24 hour drain output.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with presence of hematoma</measure>
    <time_frame>2 weeks post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who needed a post-op blood transfusion</measure>
    <time_frame>2 weeks post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>During operation, up to 4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Arthropathy Shoulder</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid (TXA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV TXA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No TXA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>IV, Total Dosage: 2 grams (1 gram before surgical incision + 1 gram, 3 hours after first dose)</description>
    <arm_group_label>Tranexamic acid (TXA)</arm_group_label>
    <other_name>TXA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients older than 18 years old&#xD;
&#xD;
          2. Patients younger than 90 years old&#xD;
&#xD;
          3. Patients undergoing scheduled revision total shoulder arthroplasty&#xD;
&#xD;
          4. Patients who consent to be randomized&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients younger than 18&#xD;
&#xD;
          2. Patients older than 90 years old&#xD;
&#xD;
          3. Patients who are pregnant or breast-feeding women&#xD;
&#xD;
          4. Patients who are allergic to tranexamic acid&#xD;
&#xD;
          5. Patients with proximal humerus fracture or fracture sequelae&#xD;
&#xD;
          6. Patients who use estrogen containing medications (i.e. oral contraceptive pills)&#xD;
&#xD;
          7. Patients who have acquired disturbances of color vision&#xD;
&#xD;
          8. Patients with a history of any of the following diagnosis: '&#xD;
&#xD;
               -  Subarachnoid hemorrhage&#xD;
&#xD;
               -  Active intravascular clotting&#xD;
&#xD;
               -  Severe pulmonary disease (FEV &lt;50% normal)&#xD;
&#xD;
               -  Plasma creatinine &gt; 115 μmol/L in males, &gt; 100 μmol/L in females, or hepatic&#xD;
                  failure)&#xD;
&#xD;
               -  (Renal impairment serum creatinine &gt; 1.5 times the upper limit of normal NYU)&#xD;
&#xD;
               -  Preoperative anemia [Hemoglobin (Hb) &lt; 11g/dL in females, Hb &lt; 12 g/dL in males]&#xD;
&#xD;
          9. Patients who refuse blood products&#xD;
&#xD;
         10. Patients undergoing hormone replacement therapy&#xD;
&#xD;
         11. Patients with diagnosed or self-reported cognitive dysfunction;&#xD;
&#xD;
         12. Patients who are unable to understand or follow instructions;&#xD;
&#xD;
         13. Patients with severe liver disease, renal insufficiency, congestive heart failure,&#xD;
             and/or significant heart disease;&#xD;
&#xD;
         14. Patients with BMI over 50&#xD;
&#xD;
         15. Any patient that the investigators feel cannot comply with all study related&#xD;
             procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uchenna Umeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uchenna Umeh, MD</last_name>
    <phone>212-598-6085</phone>
    <email>Uchenna.Umeh@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan Caruci</last_name>
    <phone>212-598-6085</phone>
    <email>Juan.Caruci@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Langone Orthopedic Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uchenna Umeh, MD</last_name>
      <email>Uchenna.Umeh@nyulangone.org</email>
    </contact>
    <contact_backup>
      <last_name>Juan Caruci</last_name>
      <email>Juan.Caruci@nyulangone.org</email>
    </contact_backup>
    <investigator>
      <last_name>Uchenna Umeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arthur Hertling, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young Kwon, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mandeep Virk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Zuckerman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesse Ng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Germaine Cuff, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>November 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data upon reasonable request. Requests should be directed to Uchenna.Umeh@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

